The combination of RY103 and sunitinib significantly downregulated the protein expressions of CD34 and ATF4, indicating an effective blockage of the GCN2 pathway and thus suppression of tumor angiogenesis (Figure 7F). The gene discussed is CD34; the disease is neoplasm.